Newsbenzinga
FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens
· Published
Article summary
FDA Expands Merck CAPVAXIVE Use To At-Risk Children And Adolescents Aged 2-17 Following Positive Phase 3 STRIDE-13 Data.
An excerpt from the original article.
Comments —
Loading comments…